维生素D3二羟基代谢产物对尿毒症患者钙吸收的影响。

Effect of dihydroxylated metabolites of vitamin D3 on calcium absorption in uraemic man.

Muirhead N, Catto G R, Gvozdanovic S, Gvozdanovic D, Edward N

Clin Sci (Lond). 1981 Dec;61(6):723-7. doi: 10.1042/cs0610723.

Abstract

Peak 47Ca absorption and 7 day 47Ca retention were measured by a whole-body radioactivity counting technique in 10 haemodialysis patients before and after treatment with 1,25-dihydroxycholecalciferol [1,25-(OH)2D3] and 24,25-dihydroxycholecalciferol [24,25-(OH)2D3]. 2. Before treatment all patients had low peak 47Ca absorption and 7 day 47Ca retention. 3. After treatment with 1,25-(OH)2D3 (0 . 25-l microgram/day for 4-12 months) peak 47Ca absorption and 7 day 47Ca retention returned to normal. 4. After treatment with 24,25-(OH)2D3 (2 microgram/day for 4-12 months) peak 47Ca absorption and 7 day 47Ca retention remained at pretreatment levels. 5. It is concluded that physiological doses of 24,25-(OH)2D3 have no effect on calcium absorption or retention in uraemic man.

摘要

采用全身放射性计数技术，在10例血液透析患者接受1,25 - 二羟胆钙化醇[1,25-(OH)₂D₃]和24,25 - 二羟胆钙化醇[24,25-(OH)₂D₃]治疗前后，测量其⁴⁷Ca的吸收峰值和7天⁴⁷Ca潴留量。2. 治疗前，所有患者的⁴⁷Ca吸收峰值和7天⁴⁷Ca潴留量均较低。3. 用1,25-(OH)₂D₃（0.25 - 1微克/天，持续4 - 12个月）治疗后，⁴⁷Ca吸收峰值和7天⁴⁷Ca潴留量恢复正常。4. 用24,25-(OH)₂D₃（2微克/天，持续4 - 12个月）治疗后，⁴⁷Ca吸收峰值和7天⁴⁷Ca潴留量维持在治疗前水平。5. 得出结论：生理剂量的24,25-(OH)₂D₃对尿毒症患者的钙吸收或潴留无影响。